Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

OXC4P1-105: A Phase I Study of the Safety, Tolerability, and Antitumor Activity of Escalating Doses of Combretastatin A4 Phosphate Given in Combination With Bevacizumab to Subjects With Advanced Solid Tumors

NCT00395434 is registered in ClinicalTrials.gov with Mateon Therapeutics as lead sponsor.

NCT NCT00395434
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00395434 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
OXC4P1-105: A Phase I Study of the Safety, Tolerability, and Antitumor Activity of Escalating Doses of Combretastatin A4 Phosphate Given in Combination With Bevacizumab to Subjects With Advanced Solid Tumors
Lead sponsor
Mateon Therapeutics
Phase
Phase 1
Overall status
Completed
Start date
September 30, 2006
Completion date
January 31, 2007
Enrollment
20 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

tumors